Counteracting muscle wasting in HIV-infected individuals

W. D. Dudgeon, K. D. Phillips, James Carson, R. B. Brewer, J. L. Durstine, G. A. Hand

Research output: Contribution to journalReview article

72 Citations (Scopus)

Abstract

HIV-infected persons often experience a loss of lean tissue mass, which includes decreases in skeletal muscle mass. This HIV-associated wasting is significant because it has been associated with accelerated disease progression and increased morbidity. Signalling related to several circulating molecules, including tumour necrosis factor (TNF)-α, growth hormone, insulin-like growth factor (IGF)-1 and testosterone, has been associated with the aetiology of muscle wasting. Additionally, nutritional status related to malnutrition and specific dietary deficiencies may be involved. In an attempt to counter muscle wasting in HIV-infected persons, treatments have been suggested that target these mechanisms. Nutritional supplementation, cytokine reduction, hormone therapy and resistance exercise training are potential treatments for this condition. Resistance exercise training, which is more easily accessible to this population than other treatments, holds promise in counteracting the process of HIV wasting, as it has been successfully used to increase lean tissue mass in healthy and clinical populations. This review will explore the HIV/AIDS muscle-wasting syndrome, its aetiology, and the treatments used to counteract wasting.

Original languageEnglish (US)
Pages (from-to)299-310
Number of pages12
JournalHIV Medicine
Volume7
Issue number5
DOIs
StatePublished - Jul 1 2006

Fingerprint

HIV
Muscles
Resistance Training
HIV Wasting Syndrome
Exercise
Therapeutics
Somatomedins
Nutritional Status
Malnutrition
Population
Growth Hormone
Disease Progression
Skeletal Muscle
Tumor Necrosis Factor-alpha
Hormones
Cytokines
Morbidity

All Science Journal Classification (ASJC) codes

  • Virology
  • Medicine(all)
  • Immunology

Cite this

Dudgeon, W. D., Phillips, K. D., Carson, J., Brewer, R. B., Durstine, J. L., & Hand, G. A. (2006). Counteracting muscle wasting in HIV-infected individuals. HIV Medicine, 7(5), 299-310. https://doi.org/10.1111/j.1468-1293.2006.00380.x

Counteracting muscle wasting in HIV-infected individuals. / Dudgeon, W. D.; Phillips, K. D.; Carson, James; Brewer, R. B.; Durstine, J. L.; Hand, G. A.

In: HIV Medicine, Vol. 7, No. 5, 01.07.2006, p. 299-310.

Research output: Contribution to journalReview article

Dudgeon, WD, Phillips, KD, Carson, J, Brewer, RB, Durstine, JL & Hand, GA 2006, 'Counteracting muscle wasting in HIV-infected individuals', HIV Medicine, vol. 7, no. 5, pp. 299-310. https://doi.org/10.1111/j.1468-1293.2006.00380.x
Dudgeon WD, Phillips KD, Carson J, Brewer RB, Durstine JL, Hand GA. Counteracting muscle wasting in HIV-infected individuals. HIV Medicine. 2006 Jul 1;7(5):299-310. https://doi.org/10.1111/j.1468-1293.2006.00380.x
Dudgeon, W. D. ; Phillips, K. D. ; Carson, James ; Brewer, R. B. ; Durstine, J. L. ; Hand, G. A. / Counteracting muscle wasting in HIV-infected individuals. In: HIV Medicine. 2006 ; Vol. 7, No. 5. pp. 299-310.
@article{2e49539423694b37a0001ad365b59d2a,
title = "Counteracting muscle wasting in HIV-infected individuals",
abstract = "HIV-infected persons often experience a loss of lean tissue mass, which includes decreases in skeletal muscle mass. This HIV-associated wasting is significant because it has been associated with accelerated disease progression and increased morbidity. Signalling related to several circulating molecules, including tumour necrosis factor (TNF)-α, growth hormone, insulin-like growth factor (IGF)-1 and testosterone, has been associated with the aetiology of muscle wasting. Additionally, nutritional status related to malnutrition and specific dietary deficiencies may be involved. In an attempt to counter muscle wasting in HIV-infected persons, treatments have been suggested that target these mechanisms. Nutritional supplementation, cytokine reduction, hormone therapy and resistance exercise training are potential treatments for this condition. Resistance exercise training, which is more easily accessible to this population than other treatments, holds promise in counteracting the process of HIV wasting, as it has been successfully used to increase lean tissue mass in healthy and clinical populations. This review will explore the HIV/AIDS muscle-wasting syndrome, its aetiology, and the treatments used to counteract wasting.",
author = "Dudgeon, {W. D.} and Phillips, {K. D.} and James Carson and Brewer, {R. B.} and Durstine, {J. L.} and Hand, {G. A.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1111/j.1468-1293.2006.00380.x",
language = "English (US)",
volume = "7",
pages = "299--310",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Counteracting muscle wasting in HIV-infected individuals

AU - Dudgeon, W. D.

AU - Phillips, K. D.

AU - Carson, James

AU - Brewer, R. B.

AU - Durstine, J. L.

AU - Hand, G. A.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - HIV-infected persons often experience a loss of lean tissue mass, which includes decreases in skeletal muscle mass. This HIV-associated wasting is significant because it has been associated with accelerated disease progression and increased morbidity. Signalling related to several circulating molecules, including tumour necrosis factor (TNF)-α, growth hormone, insulin-like growth factor (IGF)-1 and testosterone, has been associated with the aetiology of muscle wasting. Additionally, nutritional status related to malnutrition and specific dietary deficiencies may be involved. In an attempt to counter muscle wasting in HIV-infected persons, treatments have been suggested that target these mechanisms. Nutritional supplementation, cytokine reduction, hormone therapy and resistance exercise training are potential treatments for this condition. Resistance exercise training, which is more easily accessible to this population than other treatments, holds promise in counteracting the process of HIV wasting, as it has been successfully used to increase lean tissue mass in healthy and clinical populations. This review will explore the HIV/AIDS muscle-wasting syndrome, its aetiology, and the treatments used to counteract wasting.

AB - HIV-infected persons often experience a loss of lean tissue mass, which includes decreases in skeletal muscle mass. This HIV-associated wasting is significant because it has been associated with accelerated disease progression and increased morbidity. Signalling related to several circulating molecules, including tumour necrosis factor (TNF)-α, growth hormone, insulin-like growth factor (IGF)-1 and testosterone, has been associated with the aetiology of muscle wasting. Additionally, nutritional status related to malnutrition and specific dietary deficiencies may be involved. In an attempt to counter muscle wasting in HIV-infected persons, treatments have been suggested that target these mechanisms. Nutritional supplementation, cytokine reduction, hormone therapy and resistance exercise training are potential treatments for this condition. Resistance exercise training, which is more easily accessible to this population than other treatments, holds promise in counteracting the process of HIV wasting, as it has been successfully used to increase lean tissue mass in healthy and clinical populations. This review will explore the HIV/AIDS muscle-wasting syndrome, its aetiology, and the treatments used to counteract wasting.

UR - http://www.scopus.com/inward/record.url?scp=33744482887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744482887&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2006.00380.x

DO - 10.1111/j.1468-1293.2006.00380.x

M3 - Review article

VL - 7

SP - 299

EP - 310

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 5

ER -